Pharma BD Deal Intelligence
The merger of Sanofi (backed by Elf Aquitaine) and Synthelabo (backed by L'Oreal) created Sanofi-Synthelabo—a French national champion. At $11B, the deal was orchestrated by parent companies building a globally competitive pharma platform that later acquired Aventis for $60B+.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Elf's Sanofi and L'Oreal's Synthelabo announce merger to create a major French pharmaceutical company.
In 1999, Sanofi acquired Synthelabo, another French pharmaceutical company, for $8.5 billion, forming Sanofi-Synthelabo.
A look back at Sanofi's merger with Synthelabo, which was completed on May 18, 1999.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Sanofi (owned by Elf Aquitaine) and Synthelabo (owned by L'Oreal) merged in late 1998/1999 to create Sanofi-Synthelabo, a major French pharmaceutical company. The deal was driven by parent companies seeking to create a globally competitive pharma platform. Sanofi-Synthelabo later acquired Aventis in 2004 to become Sanofi-Aventis.
900K US cases/yr · $5.0B Global Antiplatelet Market (early 2000s)
Thrombotic events drive the ~805,000 heart attacks (605,000 first-time) and ~795,000 strokes the CDC reports each year in the US; 87% of strokes are ischemic. P2Y12 antiplatelet inhibitors such as clopidogrel (Plavix) block ADP-mediated platelet aggregation and, alone or with aspirin (DAPT), are guideline standard after ACS, PCI, and ischemic stroke for secondary prevention.
Beyond Plavix, Synthelabo contributed Ambien/Stilnox (zolpidem), the world's leading insomnia prescription generating over $2B in peak sales. The merger created a platform for Sanofi's subsequent hostile takeover of Aventis in 2004, forming Sanofi-Aventis, then the world's third-largest pharma company.
Sanofi SA completed its acquisition of Synthelabo S.A. for $11B. Sanofi (owned by Elf Aquitaine) and Synthelabo (owned by L'Oreal) merged in late 1998/1999 to create Sanofi-Synthelabo, a major French pharmaceutical company.
Divested beauty, diagnostics, animal health to focus on pure-play pharma. Part of Sanofi SA's $11B deal to acquire Synthelabo S.A..
Became Sanofi-Aventis, one of world largest pharma companies. Part of Sanofi SA's $11B deal to acquire Synthelabo S.A..
Created platform for $65B Aventis deal, building today Sanofi. Assessment of Sanofi SA's $11B acquisition of Synthelabo S.A. and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Synthelabo S.A. (this deal) | 1998 | $11.0B | 84 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
| Sanofi SA / Protein Sciences Corp. | 2017 | $650M | 72 |
← Browse all deals · How we score deals
More: 1998 deals · Sanofi SA deals · Cardiovascular deals